Biocon Inaugurates First US Manufacturing Facility in New Jersey

Indian biopharmaceutical giant Biocon Limited has marked its US expansion with the opening of a state-of-the-art manufacturing plant in Cranbury, New Jersey. The facility, inaugurated on September 10, 2025, signals the company's strategic push into the American generics market.

New Jersey Governor Phil Murphy joined Biocon Chairperson Kiran Mazumdar-Shaw at the ceremony, underscoring the project's regional significance. The acquired Eywa Pharma site now boasts a 2 billion tablet annual capacity after $30 million in upgrades.

With US FDA-approved formulations already in production, the facility strengthens Biocon's vertically integrated supply chain for diabetes, cancer, and autoimmune treatments. The Cranbury location provides critical proximity to US healthcare partners, potentially reducing delivery times for the Bangalore-based firm's generic drug portfolio.